Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know.

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...

The market awaits DexCom's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...

DexCom is down 16.6% since the beginning of the year, and at $65.44 per share, it is trading 27.9% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s ...

Shares of DexCom Inc. DXCM slipped 4.35% to $65.12 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 2.71% to 6,552.51 and Dow ...

From cardiac ablation devices to OTC glucose sensors, explore how breakthrough medical technologies are disrupting ...